Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported in substance: the quote is verbatim from 21 CFR 202.1(e)(7)(iii), which is an operative regulatory provision, not an example, definition, or preamble commentary. The locator matches.
- Conditional framing preserved correctly: (e)(7) is headed 'Advertisements that may be false, lacking in fair balance, or otherwise misleading,' and the rule statement says 'may be misleading' rather than 'is prohibited.' No inflation on that axis.
- Overstated on scope: the operative clause reads 'Uses statistical analyses and techniques ON A RETROSPECTIVE BASIS to discover and cite findings not soundly supported by the study, OR to suggest scientific validity and rigor for data from studies the design or protocol of which are not amenable to formal statistical evaluations.' The phrase 'on a retrospective basis' modifies the shared verb and governs both infinitive purposes, including the one quoted. The rule omits it and therefore reaches any statistical treatment of an ill-suited design, which is broader than (iii) states.
- The omission also collapses (iii) into a neighboring provision: the general case of statistics applied to invalidating study designs is separately covered by (e)(7)(v) ('derived from clinical studies the design, data, or conduct of which substantially invalidate the application of statistical analyses'). The retrospective qualifier is the distinguishing feature of the cited subparagraph, so dropping it misattributes (v)'s coverage to (iii).
- applies_when is missing an obvious limit present in the source: 21 CFR 202.1 governs prescription-drug advertisements (and, per (l)(2), specified labeling pieces). Tagging only 'promotional' would sweep in OTC promotional material the cited provision does not reach.
- determinism: judgment is correct - whether a study design is 'amenable to formal statistical evaluations' turns on methodological opinion, not presence/absence or literal match. The escalation note is consistent with this.
- authority: binding is correct - this is a codified federal regulation, not guidance.
- atomic holds: the drafter isolated only the second prong of (iii) and did not bundle in the first prong ('to discover and cite findings not soundly supported by the study'), leaving one checkable requirement.
- severity: warning is defensible, since (e)(7) provisions are framed as conduct that 'may be' violative, in contrast to the flat violations enumerated under (e)(6).
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is verbatim from the operative regulatory text of 21 CFR 202.1(e)(7)(iii) as reproduced in the source, within the enumerated list introduced by 'An advertisement may be false, lacking in fair balance, or otherwise misleading or otherwise violative of section 502(n) of the act if it:'. It is operative regulatory text, not an example, definition, or preamble.
- Not overstated: the rule statement preserves the regulation's own hedge ('may be misleading') rather than converting it into a flat prohibition, and it does not extend beyond prescription drug advertising, which is the scope of 21 CFR 202.1 ('Prescription-drug advertisements').
- Atomic: (e)(7)(iii) contains two independent prongs — (a) retrospective analysis used to discover/cite findings not soundly supported, and (b) retrospective analysis used to suggest validity/rigor for designs not amenable to formal statistical evaluation. The rule statement and check address only prong (b), so the rule as written is a single checkable requirement. The quote carries the full clause including prong (a), which is acceptable as the cited locator text but means the corpus should not treat prong (a) as covered by this rule.
- determinism = judgment is correct: whether a study's design or protocol is 'amenable to formal statistical evaluations' and whether the presentation 'suggests scientific validity and rigor' cannot be settled by literal match or presence/absence; it requires statistical and methodological assessment. The escalation note correctly identifies this.
- authority = binding is correct: 21 CFR 202.1 is a codified regulation, not guidance. The 'may be' framing in (e)(7) goes to the standard of violation, not to the bindingness of the source.
- applies_when is justified and not invented: promotional + drug + prescription tracks the regulation's title and the paragraph (e)(6)/(e)(7) framing of 'An advertisement for a prescription drug'. No obvious limit is missing.
- severity = warning is defensible: (e)(7) items 'may be' violative (as contrasted with (e)(6) items that are violative), so a flag-for-review severity rather than a hard block matches the regulatory posture.
- Locator 21 CFR 202.1(e)(7)(iii) matches the clause quoted.